



**UROPLASTY TO PRESENT AT ROTH CAPITAL PARTNERS 20TH
ANNUAL OC GROWTH STOCK CONFERENCE**

MINNEAPOLIS, MN, February 6, 2008 – Uroplasty, Inc. (AMEX: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that it will be presenting at the ROTH Capital Partners OC Growth Conference on Wednesday, February 20, 2008 at the Ritz Carlton Laguna Nigel. David Kaysen, Uroplasty’s President and CEO, and Medi Jiwani, Uroplasty’s Vice President and CFO, will present the Company’s business strategy and financial results at 4:00 p.m. Pacific Time.

Attendance at the conference is by invitation only. A live audio-only webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at Uroplasty’s website at www.uroplasty.com. An archived replay of the presentation will also be available shortly after the live presentation at Uroplasty’s website.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC® system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder symptoms (OAB). We also offer Macroplastique® Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:

Uroplasty, Inc.
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, and
Treasurer,
952.426.6140

EVC Group
Matthew Selinger (Investors)
415.896.6817
Chris Gale (Media)
646.201.5445